Skip to main content

May-16

05/17/2016
Managing Mental Health is a 3-part series dedicated to exploring the challenges managed care professionals face regarding the treatment of mental health illnesses, with a specific focus on dementia, schizophrenia, and depression.
Managing Mental Health is a 3-part series dedicated to exploring the challenges managed care professionals face regarding the treatment of mental health illnesses, with a specific focus on dementia, schizophrenia, and depression.
Managing Mental Health is a...
05/17/2016
First Report Managed Care
Department
05/17/2016
As the prevalence of diabetes grows, so does the number of insulin products on the market.
As the prevalence of diabetes grows, so does the number of insulin products on the market.
As the prevalence of diabetes...
05/17/2016
First Report Managed Care
05/17/2016
At a recent AMCP industry workshop, experts highlighted the need to look to the European market experience with biosimilars.
At a recent AMCP industry workshop, experts highlighted the need to look to the European market experience with biosimilars.
At a recent AMCP industry...
05/17/2016
First Report Managed Care
05/17/2016
Effects of forced vital capacity decline and suspected early acute idiopathic pulmonary fibrosis exacerbation on utilization and outcomes were recently discussed.
Effects of forced vital capacity decline and suspected early acute idiopathic pulmonary fibrosis exacerbation on utilization and outcomes were recently discussed.
Effects of forced vital capacity...
05/17/2016
First Report Managed Care
Department
05/17/2016
A treatment strategy with Xeljanz (tofacitinib) after one tumor necrosis factor inhibitor for RA is more cost-effective than tofacitinib following 2 TNF inhibitors.
A treatment strategy with Xeljanz (tofacitinib) after one tumor necrosis factor inhibitor for RA is more cost-effective than tofacitinib following 2 TNF inhibitors.
A treatment strategy with...
05/17/2016
First Report Managed Care
Department
05/17/2016
Treatment with alemtuzumab (Lemtrada, Genzyme) for relapsing-remitting multiple sclerosis (RRMS) demonstrated a cost savings compared with subcutaneous interferonß-1a due to cost avoidance in relapse reduction and drug cost associated with...
Treatment with alemtuzumab (Lemtrada, Genzyme) for relapsing-remitting multiple sclerosis (RRMS) demonstrated a cost savings compared with subcutaneous interferonß-1a due to cost avoidance in relapse reduction and drug cost associated with...
Treatment with alemtuzumab...
05/17/2016
First Report Managed Care
Department
05/17/2016
A Crippling Burden for US Stakeholders
A Crippling Burden for US Stakeholders
A Crippling Burden for US...
05/17/2016
First Report Managed Care
05/17/2016
The AMA wants to ban Direct to Consumer (DTC) advertising of prescription drugs and medical devices. Our expert pannel offer their take on whether DTC ads lead to higher cost or more informed patients.
The AMA wants to ban Direct to Consumer (DTC) advertising of prescription drugs and medical devices. Our expert pannel offer their take on whether DTC ads lead to higher cost or more informed patients.
The AMA wants to ban Direct to...
05/17/2016
First Report Managed Care
05/17/2016
On Monday, April 25, 2016, the Centers for Medicare & Medicaid Services (CMS) released its final rule updating managed care in Medicaid and the Children’s Health Insurance Program (CHIP). Overall, nearly 900 individuals and organizations...
On Monday, April 25, 2016, the Centers for Medicare & Medicaid Services (CMS) released its final rule updating managed care in Medicaid and the Children’s Health Insurance Program (CHIP). Overall, nearly 900 individuals and organizations...
On Monday, April 25, 2016, the...
05/17/2016
Population Health